Imagine a tiny, precise 'lightning bolt' that can zap away cancer cells without burning the healthy tissue around them. This technology uses a special kind of cold gas delivered through a thin tube, similar to how a straw works, to reach deep inside the body. It uses computer simulations to make sure the treatment is perfectly tailored to each patient's specific tumor shape.
Pancreatic and biliary tract cancers have a poor prognosis and are difficult to treat due to their location in sensitive areas. Current surgical options often cause significant damage to healthy surrounding tissue.
A cold atmospheric pressure plasma (CAP) hardware platform and a multiscale in-silico simulation model for personalized cancer treatment.
If you are an endoscopic tool manufacturer dealing with the lack of non-thermal ablation tools for sensitive organs — this project developed a cold atmospheric plasma platform that allows for precise cancer removal with minimal side effects.
If you are a software provider dealing with the need for better pre-surgery planning — this project developed a multiscale in-silico model that combines plasma fluid and solid tumor simulations to determine the best operational window.
If you are a clinic dealing with the poor prognosis of pancreatic and biliary tract cancers — this project developed a personalized treatment system using Bayesian optimization to deliver the exact dose of therapeutic agents.
Based on available project data, there is no specific pricing or unit cost mentioned for the final medical platform.
The project is currently laying the foundation for market introduction and clinical trials, but specific industrial scaling metrics are not yet provided.
Based on available project data, the project is in the development and in-vivo testing phase; specific patent or licensing agreements are not listed.
The platform integrates with pre-surgery diagnostics such as MRI and ultrasound to initialize the in-silico model and determine the operational window.
The project period runs from 2024-04-01 to 2028-03-31, with the goal of laying the foundation for clinical trials and market introduction.
The consortium consists of 6 partners across 4 countries, showing a strong academic lean with 3 universities and 2 research organizations. However, there is a 17% industry ratio including 1 SME, indicating that while the project is research-heavy, there is an established link to commercialize the technology.
Contact the University of Cyprus regarding the IgnitePLASMA platform
Contact us to find licensing opportunities for cold plasma surgical tools.
